+ + data and comments + +, page-12

re: + + phase ii, nsclc trial + + Extract:

"We have seen positive signs in the PI-88 Phase I single agent trial where over 40% of the melanoma patients showed tumor growth retarded for periods lasting up
to 30 months

and from the Phase II multiple myeloma trial where 39% of patients have shown cancer stabilization for periods up to 2 years".

Comment: These are highly significant results. And as far as I know the first meaningful result of any Melanoma cancer trial.

Melanoma is a most dreaded disease and treatment agents fear to tread in this field.

Phase I was very succesfull and if Phase II is, then there is a possibility that some concessions can be obtained from the FDA.

And what about selling this drug if proven successful?

At this stage, there would be a big demand for it IMHO.

Gerry
Readers, please do your own research and you decide if and when to buy, hold or sell any stocks.